Two-drug combination boosts survival in metastatic prostate cancer

August 05, 2015

BOSTON -- Newly diagnosed patients with metastatic, hormone-sensitive prostate cancer gained a dramatic survival benefit when started on two drugs simultaneously, rather than delaying the second drug until the cancer began to worsen, according to results of a clinical trial led by a Dana-Farber Cancer Institute scientist.

Patients who underwent six cycles of treatment with the chemotherapy drug docetaxel along with a hormone blocker survived for a median of 57.6 months, more than a year longer than the median 44-month survival for men who received only the hormone-blocker, according to a report in The New England Journal of Medicine. The immediate combination also prolonged the period before the cancer began to worsen - a median of 20.2 months versus 11.7 months with the single agent.

The multi-center, phase III trial, involving 790 patients, "is the first to identify a strategy that prolongs survival in men newly diagnosed with metastatic, hormone-sensitive prostate cancer," said Christopher J. Sweeney, MBBS, of Dana-Farber's Lank Center for Genitourinary Oncology. He said the results of the multi-center phase III trial should change the way doctors have routinely treated such patients since the 1940s.

Sweeney had reported initial results of the trial in June 2014 at the annual meeting of the American Society of Clinical Oncology (ASCO), and they were so favorable that the new regimen has been adopted by some physicians. Since then, confirmatory data from a trial called STAMPEDE were presented at the 2015 ASCO meeting, and those results, along with the new publication in the NEJM, are the final pieces "required for treatment guidelines to be updated around the globe," Sweeney said.

It has been standard practice for decades to treat this group of prostate cancer patients with hormone blockers, withholding chemotherapy until the hormone blockers become ineffective, which they do, on average, in about three years.

The new trial was designed and conducted by the ECOG-ACRIN Cancer Research Group to test Sweeney's hypothesis that adding chemotherapy to hormone treatment from the start would impair the tumor cells' ability to repair damage, delaying the development of resistance.
-end-
Senior author of the report is Robert S. DiPaola, MD, of the Rutgers Cancer Institute of New Jersey.

Funding for the study included Public Health Service Grants CA180820, CA180794, CA180795, CA180802, CA180799, CA180790, CA180853, CA189829, CA180801, CA180888, CA180801, CA31946, CA180821, and from the National Cancer Institute, National Institutes of Health and the Department of Health and Human Services.

Dana-Farber Cancer Institute

Related Hormone Articles from Brightsurf:

Hormone differences
During birth, hormones in the body surge in both mother and baby, sent along by the nervous system.

How hormone therapy slows progression of atherosclerosis
As one of the most common treatments for effectively managing menopause symptoms, hormone therapy (HT) is also known to provide multiple health benefits, including slowing the progression of atherosclerosis.

What does the "love hormone" do? It's complicated
Much of what we know about the actions of neuromodulators like oxytocin comes from behavioral studies of lab animals in standard lab conditions.

Hormone systems can still be adapted in adulthood
Behavioural biologists at M√ľnster University have now been able to demonstrate for the first time that male guinea pigs are still able to adapt their hormone systems to changes in their social environment in adulthood.

A hormone -- plant style
Researchers from the Faculties of Chemistry and Biology at Bielefeld University have now found a method that might make the production of a biologically significant precursor of jasmonic acid more efficient and cheaper.

uOttawa researchers discover new sex hormone
When University of Ottawa biologists Kim Mitchell and Vance Trudeau began studying the effects of gene mutations in zebrafish, they uncovered new functions that regulate how males and females interact while mating.

Could pancreatitis be a stress hormone deficiency?
UT Southwestern researchers find that humans and mice with pancreatitis are deficient in a stress hormone called FGF21.

Hormone therapy associated with improved cognition
Estrogen has a significant role in overall brain health and cognitive function.

Bones secrete a stress hormone
Both rodents and humans release a bone-derived hormone called osteocalcin in response to acute stress, researchers report on Sept.

'Hunger hormone' enhances memory
A team of neuroscience researchers at the University of Southern California have identified a surprising new role for the 'hunger hormone' ghrelin.

Read More: Hormone News and Hormone Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.